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Nowadays, anthracyclines play an important role in chemothera-
peutic treatment of a wide variety of tumour types. The clinical use
of anthracyclines is limited by their toxicity profile, especially
irreversible, cumulative dose-related cardiotoxicity, and by
intrinsic or acquired resistance of tumours cells. Mechanisms of
this resistance consist of several pathways, such as overexpression
of drug efflux pumps (i.e. P-glycoprotein), decrease in topoiso-
merase II enzyme levels, and increase in cellular detoxifying
capacity (Kaye and Merry, 1985; Deffie et al, 1989; de Jong et al,
1990; Ford and Hait, 1990; Roninson, 1997).
Morpholinyl anthracyclines, such as methoxymorpholino
doxorubicin (MMRDX or PNU-152243), were synthesized in
search for new anthracyclines with at least partially novel modes
of action, including activity on multidrug-resistant (MDR)
tumours. MMRDX is a novel doxorubicin derivative in which the
nitrogen atom of the daunosamine is enclosed in a methoxymor-
pholino ring (Figure 1). The drug easily fluxes into cells due to its
high lipophilicity (Johnston and Glazer, 1983; Acton et al, 1984;
Streeter et al, 1986). The working mechanism of morpholinyl
anthracyclines appears to be different from other anthracyclines.
Morpholinyl anthracyclines inhibit ribosomal gene transcription as
well as topoisomerase I-mediated DNA-cleavage (Wassermann 
et al, 1988, 1990). MMRDX showed a potent cytotoxic activity in
vitro on various tumour cell lines, including MDR tumour cell
lines (Danesi et al, 1993; Kuhl et al, 1993; van der Graaf et al,
1995; Bakker et al, 1997). Metabolic conversion of MMRDX by
human liver microsomes and NADPH potentiated the cytotoxicity
in an ovarian carcinoma cell line (Lau et al, 1994). In animal
studies, MMRDX showed activity against MDR xenografts
(Ripamonti et al, 1992). However, in patients with various intrinsi-
cally anthracycline resistant solid tumours only a few tumour
responses were observed (Vasey et al, 1995; Bakker et al, 1998). A
phase I study (Vasey et al, 1995) with bolus injection of MMRDX,
showed a maximum tolerated dose (MTD) at 1.5 mg m–2 every 
3 weeks and myelosuppression (neutropenia and thrombocytopenia)
as dose-limiting toxicity (DLT). Nadirs occurred in the third week
after treatment. A broad phase II study (Bakker et al, 1998) with 1.5
mg m–2 MMRDX administered as bolus every 4 weeks also showed
myelosuppression as major toxicity. Furthermore, both studies
showed late and prolonged nausea, vomiting and transient eleva-
tions of hepatic transaminases. No signs of severe cardiotoxicity
were observed in both human studies, although two patients had to
be taken off study due to a decrease in left ventricular ejection frac-
tion (LVEF) in the phase II study (Vasey et al, 1995; Bakker et al,
1998). In addition, MMRDX showed no substantial cardiotoxicity
in rats (Danesi et al, 1993). Other anthracyclines showed less toxi-
city when administered as prolonged infusion than as bolus infu-
sion (Legha et al, 1982a, 1982b). Therefore, we decided to perform
a phase I study with MMRDX administered as a 3 h infusion every
4 weeks in order to try to increase the MTD as compared with
bolus administration. In addition, we assessed pharmacokinetics of
prolonged MMRDX-infusion.
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Summary The aim of this phase I study was to assess feasibility, pharmacokinetics and toxicity of methoxymorpholino doxorubicin (MMRDX
or PNU-152243) administered as a 3 h intravenous infusion once every 4 weeks. Fourteen patients with intrinsically anthracycline-resistant
tumours received 37 cycles of MMRDX. The first cohort of patients was treated with 1 mg m–2 of MMRDX. The next cohorts received 
1.25 mg m–2 and 1.5 mg m–2 respectively. Common toxicity criteria (CTC) grade III/IV nausea and vomiting were observed in 1/18 cycles at
1.25 mg m–2 and in 2/11 cycles at 1.5 mg m–2. Transient elevation in transaminases up to CTC grade III was observed in 2/16 cycles at 
1.25 mg m–2 and 4/11 cycles at 1.5 mg m–2. No cardiotoxicity was observed. At 1.25 mg m–2 CTC grade IV neutropenia occurred in 1/17
cycles. At 1.5 mg m–2 CTC grade III neutropenia was seen in 2/7 and grade IV in 3/7 evaluable cycles. Thrombocytopenia grade III was
observed in 2/9 and grade IV in 1/9 evaluable cycles. One patient treated at 1.5 mg m–2 died with neutropenic fever. Therefore, dose-limiting
toxicity was reached and 1.25 mg m–2 was considered the maximum tolerated dose for MMRDX as 3 h infusion. No tumour responses were
observed. Pharmacokinetic parameters showed a rapid clearance of MMRDX from the circulation by an extensive tissue distribution. Renal
excretion of the drug and its metabolite was negligible. In conclusion, prolongation of MMRDX infusion to 3 h does not improve the toxicity
profile as compared with bolus administration. © 2000 Cancer Research Campaign
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Patients
The study was performed between December 1994 and June 1996.
Patients with intrinsic anthracycline-resistant tumours were
accrued in three different centres in Belgium and The Netherlands.
Eligible were patients with histologically confirmed non-small-
cell lung cancer (NSCLC), mesothelioma, head and neck,
colorectal, renal, cervical cancer or adenocarcinoma of unknown
origin, either metastatic or unresectable, not amenable to curative
therapy. For colorectal cancer prior adjuvant chemotherapy ³ 12
months or 5-fluorouracil (5-FU) treatment ³ 6 weeks before study
entry was allowed. For head and neck cancer prior chemotherapy
as radiosensitization ³ 6 weeks before study entry was allowed.
Previous radiotherapy involving not more than 25% of bone
marrow reserve was allowed but should have been completed 
for at least 4 weeks. Further inclusion criteria were an Eastern
Cooperation Oncology Group performance status (PS ECOG) ≤ 2,
life expectancy ³ 3 months, neutrophils ³ 2.0 ´ 109 l–1, platelets 
³ 150 ´ 109 1–1, creatinine ≤ 1.25 times the upper normal limit, and
serum bilirubin, alkaline phosphatase, aspartate aminotransferase
(ASAT) and alanine aminotransferase (ALAT) within the normal
limits. In case of liver metastases patients were eligible if bilirubin
was normal and liver enzymes were ≤ 2.5 times the upper normal
limit. Excluded were patients with a history of prior malignancy
(except for curatively treated carcinoma in situ of the cervix or
localized epithelial skin cancer), an active infectious process, brain
or leptomeningeal disease, a history of myocardial infarction
within the last year, heart failure, arrythmias requiring permanent
medication, or uncontrolled hypertension (≤ 200/110 mmHg).
Pregnant or breast-feeding women, or fertile women refusing to
use contraceptives or mentally incapacitated patients were also
excluded. Pretreatment evaluation consisted of assessment of
complete medical history, physical examination, ECG, measure-
ment of LVEF by MUGA scan or echocardiography, and labora-
tory tests including complete blood count with differential,
electrolytes, liver and renal function tests, total protein, albumen,
glucose and urine analysis. The study was approved by all local
medical ethics committees and all patients gave written informed
consent.
Study drug and dosing
MMRDX was obtained from Pharmacia & Upjohn (Milan, Italy)
in freeze-dried vials containing 50 or 500 mg of product with
lactose as excipient. Before administration, MMRDX was
dissolved in 5 ml 0.9% sodium chloride to obtain concentrations
of 10 and 100 mg ml–1 respectively. The concentration of the
administered drug was 30–50 mg ml–1. MMRDX was administered
by a continuous intravenous (i.v.) infusion during 3 h every 28
days for a maximum of six cycles. The starting dose was 1 mg m–2
for the first three patients, and was extrapolated from the results
obtained in the previous studies with bolus administration (Vasey
et al, 1995; Bakker et al, 1998). If no DLT occurred, dose was
escalated with 0.25 mg m–2 for the next cohort of three patients.
No intra-patient dose escalation was allowed. If DLT occurred in
one out of three patients, another cohort of three patients was
entered at the same dose level. If two or more patients showed
DLT, further dose escalation was stopped. DLT was defined as
National Cancer Institute Common Toxicity Criteria (CTC) grade
IV complicated neutropenia, grade IV neutropenia lasting more
than 8 days or grade III/IV thrombocytopenia. Other DLTs were
CTC grade IV anaemia, grade ³ III renal toxicity, grade ³ III
bilirubin, transaminases grade IV, or grade ³ II at day 28, any
combination of grade ³ III clinical toxicities (except anorexia),
grade ³ I neurological toxicity, incomplete bone marrow recovery
at day 42 or cardiotoxicity (defined as clinical signs of congestive
heart failure or a decline in LVEF ³ 15% to a value above the
upper normal limit of the institution or ³ 10% to a value below the
lower normal limit). MTD was defined as the dose at which not
more than than one out of three to six patients experienced DLT,
with the next higher dose level causing DLT in two or more
patients. Treatment delay up to 2 weeks for subsequent cycles of
MMRDX was allowed if platelet count was still descending or 
< 150 ´ 109 l–1, or if absolute granulocyte count was < 2.0 ´
109 l–1. Dose reduction by 10% at dose levels 1 and 1.25 mg m–2 or
by 0.25 mg m–2 at dose level 1.5 mg m–2 was performed if febrile
neutropenia, any grade III/IV infection requiring i.v. antibiotics,
absolute granulocyte count nadir < 0.5 ´ 109 l–1 for > 8 days,
platelets nadir < 50 ´ 109 l–1, haemorrhagic diathesis occurred. If
absolute granulocyte count at day 28 < 2.0 ´ 109 l–1 or platelets at
day 28 < 150 ´ 109 l–1 occurred, but recovered after treatment
delay dose reduction was also performed. Treatment was stopped
after 2 weeks of treatment delay, if patients experienced unaccept-
able toxicity, or if patients showed progressive disease.
Anti-emetics
Thirty minutes prior to MMRDX administration, patients received
ondansetron 8 mg i.v. and dexamethasone 10 mg i.v. as anti-
emetics. Thereafter, patients took orally ondansetron 2 ´ 8 mg at
day 2 and 3, dexamethasone 2 ´ 9 mg at day 2 and dexamethasone
2 ´ 4.5 mg at day 3.
Toxicity and response
Toxicity was evaluated weekly and graded according to CTC.
Total blood count, white blood cell differential, and liver function
tests were repeated weekly during treatment. A cycle was consid-
ered evaluable for haematological toxicity, if at least one haemato-
logical evaluation during the first 2 weeks and another evaluation
between day 19 and 25 were performed. A cycle was evaluable for
transaminases if at least one evaluation was performed between
day 5 and 10, and for all other non-haematological toxicities if the
assessment was performed within the end of cycle. Whenever a
grade ³ III toxicity occurred the cycle was always considered as
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Figure 1 Chemical structures of doxorubicin and methoxymorpholino
doxorubicinevaluable. Physical examination and all laboratory tests except
urine analysis were repeated once every cycle and after treatment.
LVEF evaluation (either by MUGA-scan or echocardiography, but
each patient being followed by the same method) was performed
after every two cycles. Although tumour response was not an end
point, tumour responses were assessed according to WHO criteria
(World Health Organization, 1979) after the third and the last cycle.
Pharmacokinetics
Only patients without liver metastases were enrolled in the
pharmacokinetic part of the study. The pharmacokinetic profile of
MMRDX was studied in plasma and urine obtained from patients
in the first cycle during the first 120h. All blood samples were
collected in heparine-containing glass tubes and were protected
from light because of photosensitivity of MMRDX. Blood samples
were taken prior to the infusion of MMRDX, at 15, 30min and 1.5
h during the infusion, at the end of infusion (3h), and at 5, 15 and
30min, and at 1, 2, 4, 6, 10, 24, 48, 72, 96 and 120h thereafter.
Samples were immediately centrifuged at 1200gfor 10min at 4°C
and plasma was stored in polypropylene tubes at –20°C until
analysis. Determination of levels of MMRDX and its 13-dihydro
metabolite (FCE 26176, 13-dihydro-3¢-deamino-3¢-(2(S)-meth-
oxy-4-morpholinyl) doxorubicin) in plasma and urine was carried
out by using high performance liquid chromatography with fluo-
rescence detection by method of Breda et al (1992), with some
modifications, as described by Bakker et al (1998). The detection
limits for MMRDX and the 13-dihydro metabolite were 0.1 mg l–1
in plasma and 0.5 mg l–1 in urine.
Data analysis
The plasma and urine pharmacokinetic parameters were calculated
by standard non-compartmental analysis. Actual sampling times
were used in the calculations. Pharmacodynamic analysis was
performed by linear regression analysis between Cmax’ AUC0-tz and
percentage change in haemoglobin, platelets, leucocytes and
neutrophils during the first cycle.
RESULTS
Fourteen male patients were entered in this study. Patient charac-
teristics are shown in Table 1. Three patients were treated at dose
level 1.0mg m–2 (8 cycles), six patients at 1.25mg m–2 (18 cycles)
and five patients at 1.5mg m–2 (11 cycles). Seven patients did not
receive any form of prior anticancer therapy. In five patients 
a potential risk factor for cardiac toxicity existed (mediastinal
radiotherapy (n= 1), hypertension (n= 1), myocardial infarction
and atrial fibrillation (n= 1) and non-specific ST-T wave changes
(n= 2)). On therapy, at 1.5mg m–2, one patient died due to
pulmonary embolism and one patient died due to sepsis during
febrile neutropenia. In all other patients treatment was stopped for
reason of disease progression. No tumour response was observed
in 13 evaluable patients.
Toxicity
Thirteen patients were evaluable for haematological toxicity. Table
2 shows CTC grade III and IV haematological toxicity at the
different dose levels. No grade III/IV toxicity for haemoglobin was
observed. At the lowest dose level no grade III/IV haematological
toxicity occurred. Grade III/IV haematological toxicity was
observed in one patient at 1.25mg m–2 MMRDX, and in all five
patients at 1.5mg m–2. Grade IV neutropenia was the most
common toxicity observed in 5/9 cycles. Three patients suffered
from neutropenic fever and one of these patients died of septi-
caemia. Therefore, further dose escalation was stopped. Median
nadir blood cell counts over all evaluable cycles are shown in
Table 3. Nadirs occurred between day 15 and 29 for neutrophils
and between day 8 and 28 for platelets over all dose levels. Four
out of 11 cycles (three out of five patients) had to be reduced from
1.5mg m–2 to 1.25mg m–2 because of haematological toxicity.
Overall, there was no cumulative haematological toxicity for
subsequent cycles, except for platelets at the highest dose level.
Most common non-haematological toxicities were late nausea
and vomiting, starting around 4 days after treatment. At 1mg m–2
non-haematological toxicity did not exceed CTC grade II. In
patients treated with 1.25mg m–2 nausea, vomiting and diarrhoea
exceeded grade II in one cycle, at 1.5mg m–2, nausea and vomiting
exceeded grade II in two out of 11 cycles. Grade III/IV infection
occurred in four out of 11 cycles and grade III/IV fatigue in one
out of 11 cycles. At the end of treatment LVEF was evaluated in
nine patients. No significant decreases in LVEF were observed in
eight patients after six cycles (n= 1), four cycles (n= 1), three
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Table 1Patient characteristics
Number of patients 14
Median age in years (range) 63 (41–76)
PS ECOG
07
16
21
Diagnosis
NSCLC 4
Renal cell cancer 2
Colorectal cancer 4
Head and neck cancer 3
Mesothelioma 1
Prior treatment
Radiotherapy 4
Radio-, immuno- and chemotherapy 2
Chemo- and immunotherapy 1
Surgery 4
None 3
Table 2   Percentage of total number of evaluable cycles with
haematological toxicity
CTC grade toxicity
Dose level Number of (% of total number of cycles)
(mg m–2) cycles III IV
Leucocytes 1.0 8 0 0
1.25 17 6 0
1.5 10 40 30
Neutrophils 1.0 7 0 0
1.25 17 0 0
1.5 7 29 43
Platelets 1.0 8 0 0
1.25 17 0 0
1.5 9 22 11cycles (n = 4) and after two cycles (n = 2). One patient at the
highest dose level showed a decrease in LVEF of 13% after three
cycles, but LVEF remained in the normal range. In five patients
LVEF was not evaluated (after three cycles (n = 2) and after one
cycle (n = 3)), but no clinical signs of heart failure were observed.
Transient elevations in transaminases (ALAT and ASAT) were
observed at all dose levels. Maximum toxicity for transaminases
reached CTC grade III at dose level 1.25 mg m–2 in 2/16 cycles and
at 1.5 mg m–2 in 4/11 cycles. Transient elevations in total bilirubin
were observed at 1.25 and 1.5 mg m–2 reaching CTC grade II in
2/15 and 3/11 cycles respectively. No phlebitis at the infusion site
and no nephro- or neurotoxicity was observed.
Pharmacokinetics
Plasma samples of 12 patients were available for non-compart-
mental pharmacokinetic analysis. Mean plasma levels of
MMRDX at 1.25 mg m–2 and 1.5 mg m–2 are shown in Figure 2.
Pharmacokinetics parameters are shown in Table 4. In five patients
only Cmax, AUC0-tz, Ae and percentage of dose excreted could be
calculated due to missing samples. Differences in median Cmax
between the dose levels were statistically not significant. At 
1 mg m–2, one patient showed a high Cmax of 6.17 ng ml–1, all other
patients showed Cmax around 2.0 ng ml–1 for all dose levels.
However, AUC0-tz increased with the dose. AUC0-∞ calculated
from non-compartmental analysis was around 30 ng h ml–1 and
similar for all dose levels, based on data obtained from seven
patients. At all dose levels a rather long t z, a large Vss, and a rapid
plasma clearance was observed. Urine excretion (Ae) of MMRDX
was very low, up to 2.5% of the administered dose. Also urine
excretion of the 13-dihydro metabolite of MMRDX was low, up to
2.3% of the administered dose. Pharmacodynamic analysis
revealed no correlation between AUC0-tz or Cmax and nadirs of
haemoglobin, platelets, leucocytes and neutrophils.
DISCUSSION
This study shows that prolonged infusion of 1.5 mg m–2 MMRDX
shows more toxicity than observed after bolus infusion (Vasey et
al, 1995; Bakker et al, 1998). MTD was lowered to 1.25 mg m–2.
Late haematological toxicity around day 22 was the main toxicity.
Dose-limiting CTC grade IV neutropenia was observed in 3/7
(43%) evaluable cycles at 1.5 mg m–2, with one septic death.
Previous studies with the same dose MMRDX as bolus infusion
every 3 weeks (Vasey et al, 1995) and every 4 weeks (Bakker et al,
1998) showed grade IV neutropenia in 14% and 9% of adminis-
tered cycles respectively. Also grade III/IV thrombocytopenia
occurred more frequently after prolonged infusion of 1.5 mg m–2
MMRDX than after bolus infusion. This unexpected increase in
haematological toxicity by prolonging the infusion indicates that
MMRDX should be administered as bolus infusion.
Non-haematological toxicity was comparable to the earlier
studies with MMRDX and consisted mainly of nausea and
vomiting starting 4 days after treatment, hepatic toxicity and to a
lesser extent mucositis and fatigue. No cardiotoxicity was
observed in the present study, although follow-up was relatively
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Table 3 Median (range) nadir of blood cell counts over all evaluable cycles
Dose level Leucocytes Neutrophils Platelets
(mg m–2)( ´ 109 l–1)( ´ 109 l–1)( ´ 109 1–1)
1.0 6.0 (3.9–15.1) 3.3 (2.4–12.7) 197 (130–356)
1.25 2.7 (1.0–10.4) 1.9 (0.5–8.3) 190 (60–328)
1.5 1.4 (0.2–7.5) 0.5 (0.2–7.3) 55 (8–119)
Table 4 Pharmacokinetics parameters (median (range)) as obtained by non-compartmental analysis
Dose level in mg m–2 (number of patients)
1.0 (n = 3) 1.25 (n = 6) 1.5 (n = 3)
Cmax (ng ml–1) 2.8 (1.8–6.2) 2.3 (1.1–2.7) 1.4 (1.2–2.1)
AUC (ng h ml–1) 0-tz 9.4 (8.3–18.3) 15.1 (10.1–30.4) 21.4 (5.7–26.9)
CI (ml min–1 m–2) 540.5a 649.0 (506.3–812.3)c 741.2 (659–823.2)b
tA Xz (h) 68.6a 60.9 (45.6–88.8)c 46.5 (36.1–56.9)b
Vz (l m–2) 3209a 3942.5 (1997–4540)c 2908.5 (2574–3243)b
Vss (l m–2 2502a 2891.5 (1742–3371)c 2693.0 (2585–2801)b
Ae in urine 0–72 h (mg) 28.4 (1.6–34.7) 52.7 (6.7–68.0) 69.3 (49.0–73.6)
% Dose in urine 1.6 (0.53–1.74) 2.1 (0.35–2.6) 2.47 (1.71–2.49)
an = 1; bn = 2; cn = 4.
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Figure 2 Mean plasma levels of MMRDX at dose levels 1.25 mg m–2 and
1.5 mg m–2. Error bars indicate standard error of the mean
1
2short. Also in the previous studies no cardiotoxicity was observed,
except for two patients in the phase II study who had other risk
factors as well.
In the past, pharmacodynamic analysis has revealed correlations
between AUC and haematological toxicity for epirubicin and
doxorubicin (Jakobsen et al, 1991; Piscitelli et al, 1993). For
MMRDX, we could not find a correlation between AUC or Cmax
and haematological toxicity. Also, Bakker et al (1998) could not
establish a correlation between Cmax, AUC or levels of MMRDX 
in leucocytes and haematological or non-haematological toxicity.
Also, the calculated pharmacokinetics parameters in the present
study were similar to those obtained from bolus administration in
earlier investigations. In our study AUC0-∞ was just slightly higher
compared to bolus infusion (Bakker et al, 1998), while AUC0-∞ in
the phase I study (Vasey et al, 1995) was higher than the AUC0–∞ in
our study. Therefore, we conclude that these parameters reveal no
explanation for the increased haematological toxicity. Further
pharmacokinetics parameters were in reasonable agreement with
earlier data. The phase I study (Vasey et al, 1995) showed a t for
MMRDX of 40 h after a rapid distribution phase. Plasma clearance
was 650 ml min–1 m–2. The phase II study (Bakker et al, 1998)
showed a t of the elimination phase of 49 h, a plasma clearance of
620 ml min–1 m–2. This study also showed that leucocyte levels of
MMRDX were 400- to 600-fold higher than plasma levels. This,
together with the large Vss, long t, low renal excretion and a rapid
clearance from the circulation, indicates that MMRDX is rapidly
distributed into tissues, which is not surprising since MMRDX is a
highly lipophilic drug (Acton et al, 1984; Streeter et al, 1986).
Therefore, tissue levels might be more predictive for toxicity than
plasma levels or Cmax and AUC obtained from plasma. 
In the present study no tumour responses to MMRDX were
observed. Vasey and co-workers (Vasey et al, 1995) reported four
responses in head and neck (one out of three), cervical cancer (one
out of five), and colorectal cancer (two out of 20). The phase II
study (Bakker et al, 1998) showed one partial response in one out
of 17 NSCLC.
In conclusion, prolonged administration of MMRDX shows
more myelosuppression than bolus infusion with neutropenia as
DLT. Pharmacokinetics parameters did not explain this increase in
toxicity. Non-haematological toxicity was similar. No clear signs
of cardiotoxicity have been observed, although follow-up was
relatively short.
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